Readings Newsletter
Become a Readings Member to make your shopping experience even easier.
Sign in or sign up for free!
You’re not far away from qualifying for FREE standard shipping within Australia
You’ve qualified for FREE standard shipping within Australia
The cart is loading…
This title is printed to order. This book may have been self-published. If so, we cannot guarantee the quality of the content. In the main most books will have gone through the editing process however some may not. We therefore suggest that you be aware of this before ordering this book. If in doubt check either the author or publisher’s details as we are unable to accept any returns unless they are faulty. Please contact us if you have any questions.
The last decade has ushered in an exciting new era in the pathophysiology and treatment of atopic dermatitis (AD). In this book, we shed light on the latest breakthroughs in systemic treatments for moderate-to-severe AD. In particular, we focus on the role and indication of JAK inhibitors, the role of natural killer cells in opening doors to new therapies, newly validated treatments, disease-based community data of current treatments, and the most recent clinical efficacy data of novel agents that have revolutionized the management of moderate-to-severe AD.
$9.00 standard shipping within Australia
FREE standard shipping within Australia for orders over $100.00
Express & International shipping calculated at checkout
This title is printed to order. This book may have been self-published. If so, we cannot guarantee the quality of the content. In the main most books will have gone through the editing process however some may not. We therefore suggest that you be aware of this before ordering this book. If in doubt check either the author or publisher’s details as we are unable to accept any returns unless they are faulty. Please contact us if you have any questions.
The last decade has ushered in an exciting new era in the pathophysiology and treatment of atopic dermatitis (AD). In this book, we shed light on the latest breakthroughs in systemic treatments for moderate-to-severe AD. In particular, we focus on the role and indication of JAK inhibitors, the role of natural killer cells in opening doors to new therapies, newly validated treatments, disease-based community data of current treatments, and the most recent clinical efficacy data of novel agents that have revolutionized the management of moderate-to-severe AD.